leisure time -WSS

leisure time

author：knowledge 2025-10-01 23:00:13 - browse：91185

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare explains how it will choose drugs for negotiation

knowledge

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Flagship Pioneering launches a new biotech in two countries

Complete sequence of Y chromosome published for first time

What to do when lifesaving products contribute to climate change

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Why more medical students aren't specializing in primary care

focus

leisure time

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. Biobank has 500,000 peoples' genome sequences available

Medical records are filled with copy

Despite FDA concern, risk that CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Diagnostic tests are hitting their mathematical limits

Trump demands the U.S. pay no more for drugs than other countries … again

How to pay for weight loss drugs and save Medicare

Medical leaders decry Supreme Court decision on affirmative action

Pediatric cancer treatments threatened by a new FDA policy

leisure time

Rep. Raul Ruiz on the physician shortage and more

Flagship Pioneering launches a new biotech in two countries

ReNAgade cuts staff seven months after raising $300 million

Feds fine Medicare Advantage plans for overcharging members

How to make Best Hospitals ratings actually useful for patients

Apellis safety probe of eye disease drug centers on injection needle

knowledge

knowledge

focus

hotspot